Solitomab  (Synonyms: AMG 110; MT110)

Solitomab (AMG 110) is a bispecific anti-CD3 and anti-epithelial-cell-adhesion-molecule (EpCAM) antibody. Solitomab can be used for the research of primary uterine and ovarian carcinosarcoma cancer^[1][2].

(scFv-kappa-heavy)-(scFv-heavy-kappa)

Mouse

Solitomab (1 μg/mL; 4 hours) shows cytotoxicity to EpCAM-positive cell lines and increases the sensibility of EpCAM positive carcinosarcomas (CS) cells to T-cell-cytotoxicity^[1].
Solitomab (7 days) increases the expression level of CD25 and HLA-DR protein (T-cell activation markers) on CD8⁺ and CD4⁺ T cells^[1].
Solitomab (0-2.5 μg/mL; 4 hours) is cytotoxic to ovarian carcinoma cells and the 1 μg/mL dose shows the best tumor killing effects^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

53.94 kDa

1005198-65-1

Liquid

Colorless to light yellow

[Solitomab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  (scFv-kappa-heavy)-(scFv-heavy-kappa)

• [1]. Ferrari F, et al. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro. J Exp Clin Cancer Res. 2015 Oct 17;34:123.  [Content Brief]

  [2]. English DP, et al. Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo. Cancer. 2015 Feb 1;121(3):403-12.  [Content Brief]